Estramustine
From Wikipedia, the free encyclopedia
 |
|
 |
|
|
Estramustine
|
|
| Systematic (IUPAC) name | |
| (17-hydroxy-13-methyl-7,8,9,11,12,13,14,15,16,17- decahydro-6H-cyclopenta[a]phenanthren-3-yl) bis (2-chloroethyl)aminomethanoate | |
| Identifiers | |
| CAS number | |
| ATC code | L01 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C23H31Cl2NO3 |
| Mol. mass | 440.403 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | 20 hours |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Estramustine (Emcyt) is a chemotherapy agent used to treat prostate cancer. It is a derivative of estrogen (specifically, estradiol) with an nitrogen mustard-carbamate ester moiety that makes it a alkylating antineoplastic agent similar to mechlorethamine, with estrogen-induced specificity.
Estramustine is marketed in the United States by Pharmacia (now a subsidiary of Pfizer)
[edit] Clinical uses
Estramustine is indicated for the palliative treatment of metastatic and/or progressive carcinoma of the prostate.
